secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sagimet Biosciences Inc. (SGMT)
CIK:        0001400118
Form:       8-K
Filed at:   2023-08-21T23:59:59+00:00
Accession:  0001104659-23-093921
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sagimet Q2 net loss $6.8M; IPO raised $86.2M net; denifanstat 67% fat reduction
-------------------------------------------------------------------------------

- IPO closed July 18: 6,026,772 shares at $16; gross proceeds $96.4M, net $86.2M.
- Cash $18.5M at June 30; combined with IPO proceeds extends runway into Q1 2025.
- Phase 2b FASCINATE-2 interim: 67% denifanstat achieved ≥30% liver fat reduction vs 18% placebo (p<0.001).
- Tony Rimac appointed CFO (previously COO) after Dennis Hom departure; Liz Rozek as General Counsel & CCO.
- Net loss $13.4M for H1 2023; R&D $9.2M, G&A $4.7M; no FY2023 guidance provided.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1400118/000110465923093921/0001104659-23-093921-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1400118/000110465923093921/tm2323988d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-093921

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer